Axogen, Inc. (AXGN) Stock Price & Analysis
Axogen, Inc. (AXGN) rose 3.40% to USD 42.87 as of June 10, 2026 at 05:29 UTC, according to Nexqual real-time market data.
AXGN last closed at USD 41.46; the session ranged USD 41.08–43.02 on volume of 1,091,543 shares. Market capitalization is $2.28B, with a 52-week range of USD 9.22–45.83 (NCM). Source: Nexqual, June 10, 2026 at 05:29 UTC.
Key Statistics (as of June 10, 2026 at 05:29 UTC)
| Price | USD 42.87 |
|---|---|
| Change | ▲ 3.40% (up) |
| Previous Close | USD 41.46 |
| Open | USD 41.62 |
| Day Range | USD 41.08 – 43.02 |
| 52-Week Range | USD 9.22 – 45.83 |
| Volume | 1,091,543 shares |
| Market Cap | $2.28B |
| Exchange | NCM |
Technical Analysis (AXGN)
Nexqual's technical model rates AXGN "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 05:29 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 57.09 (neutral) |
| vs SMA50 | Above (USD 38.74) |
| MACD | 0.53 (positive) |
Analyst Ratings (AXGN)
Wall Street analysts rate AXGN "Strong Buy" based on 9 analysts, with a mean price target of USD 50.78 (range USD 48–55), per Nexqual as of June 10, 2026 at 05:29 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 50.78 |
| High Target | USD 55 |
| Low Target | USD 48 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (AXGN)
| Next Earnings Date | 2026-04-28 |
|---|---|
| EPS Estimate | USD 0.12 |
| Revenue Estimate | $67.10M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.07 vs est 0.07 ▼ miss |
| 2025-12-31 | USD 0.07 vs est 0.1 ▼ miss |
| 2025-09-30 | USD 0.12 vs est 0.07 ▲ beat |
| 2025-06-30 | USD 0.12 vs est 0.06 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:29 UTC.
Financials & Fundamentals (AXGN)
| Total Revenue | $238.10M |
|---|---|
| Revenue Growth (YoY) | +26.60% |
| Gross Margin | +75.01% |
| Operating Margin | -4.61% |
| Profit Margin | -13.21% |
| ROE | -17.96% |
| Debt / Equity | 8.43 |
| Current Ratio | 7.1 |
| Total Cash | $101.60M |
| Total Debt | $20.64M |
| Free Cash Flow | $18.29M |
Source: Nexqual, June 10, 2026 at 05:29 UTC.
Financial Health Score (AXGN)
Nexqual rates Axogen, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 05:29 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 75%, operating -5% |
| Balance Sheet | Strong — $102M cash vs $21M debt, net cash position |
| Cash Flow | Solid — FCF $18M, 8% margin |
| Efficiency | Critical — ROE -18%, ROA -2.3% |
Ownership (AXGN)
| Insider Ownership | +2.10% |
|---|---|
| Institutional Ownership | +94.63% |
| Shares Outstanding | 53.18M |
| Float | 52.04M |
| Short % of Float | +7.34% |
Source: Nexqual, June 10, 2026 at 05:29 UTC.
Leadership (AXGN)
Axogen, Inc. is led by Michael D. Dale (age 65), President, CEO & Director, per Nexqual as of June 10, 2026 at 05:29 UTC.
| President, CEO & Director | Michael D. Dale (age 65) |
|---|---|
| Chief Financial Officer | Lindsey Hartley |
| Chief Marketing Officer | Jens Schroeder Kemp (age 48) |
| Vice President of Operations | Craig A. Swandal (age 64) |
| Vice President of Finance & Investor Relations | Harold D. Tamayo |
Major Backers & Investors (AXGN)
Notable institutional backers of Axogen, Inc. include First Light Asset Management, LLC, Morgan Stanley, ArrowMark Colorado Holdings LLC, according to Nexqual as of June 10, 2026 at 05:29 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Light Asset Management, LLC | 7.53% |
| Morgan Stanley | 5.87% |
| ArrowMark Colorado Holdings LLC | 3.6% |
| Wasatch Advisors LP | 3.49% |
| Polar Capital Holdings PLC | 2.82% |
| Fidelity | 2.61% |
| Assenagon Asset Management S.A. | 2.6% |
| FMR, LLC | 2.47% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.16% |
| Vanguard Group | 9.45% |
Source: Nexqual, June 10, 2026 at 05:29 UTC.
From Axogen, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Biologics License Application Approval On December 3, 2025, the FDA approved the BLA for Avance as an acellular nerve scaffold for the treatment of adult and pediatric patients aged one month or older with sensory nerve discontinuity (≤25mm).
- The Service Provider is a FDA registered tissue establishment and an AATB accredited organization.
- The Axogen Quality System meets the requirements set forth under 21 CFR Part 1271 for HCT/Ps, including Good Tissue Practices ("GTP") and is compliant with the 21 CFR Part 820 Quality System Regulation ("QSR").
- General We are the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.
Partnerships
- We obtained certain economic development grants from state and local authorities totaling up to $2.7 million including $1.3 million of cash grants to offset costs to acquire and develop the APC Facility.
- In partnership with leading surgeons and healthcare providers, our team works to reverse legacy non-coverage policies for Avance Products and Axoguard products.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATRC | AtriCure, Inc. | USD 27.3 | ▲ 0.74% |
| BLFS | BioLife Solutions, Inc. | USD 27.55 | ▲ 3.38% |
| ANAB | AnaptysBio, Inc. | USD 51.63 | ▲ 2.5% |
| TCMD | Tactile Systems Technology, Inc | USD 26.34 | ▲ 3.7% |
| LIVN | LivaNova PLC | USD 77.17 | ▲ 6.65% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:29 UTC. This page is informational and not investment advice.